Abstract
This chapter provides an overview of bromelain-treated erythrocyte autoantibodies. Normal and autoimmune murine spleen cells secrete antibodies that react with antigens buried in the erythrocyte membrane, but are exposed by the proteolytic enzyme bromelain. Trimethylammonium (TMA)-containing compounds were found to prevent the lysis of bromelain-treated mouse red blood cells (BrMRBC) caused by New Zealand black (NZB) mice-derived monoclonal immunoglobulin M (IgM) antierythrocyte antibodies. The method used to detect antibodies to bromelain-treated erythrocytes is the complement-dependent plaque test. Other methods include a rapid and sensitive enzyme-linked immunosorbent assay with fixed target cells as antigens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
